Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial

IMPORTANCE: MET inhibitors have recently demonstrated clinical activity in patients with MET exon 14 (METex14)-skipping non–small cell lung cancer (NSCLC); however, data with longer follow-up and in larger populations are needed to further optimize therapeutic approaches. OBJECTIVE: To assess the lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazieres, Julien, Paik, Paul K., Garassino, Marina C., Le, Xiuning, Sakai, Hiroshi, Veillon, Remi, Smit, Egbert F., Cortot, Alexis B., Raskin, Jo, Viteri, Santiago, Wu, Yi-Long, Yang, James C. H., Ahn, Myung-Ju, Ma, Rui, Zhao, Jun, O’Brate, Aurora, Berghoff, Karin, Bruns, Rolf, Otto, Gordon, Johne, Andreas, Felip, Enriqueta, Thomas, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240398/
https://www.ncbi.nlm.nih.gov/pubmed/37270698
http://dx.doi.org/10.1001/jamaoncol.2023.1962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240398/
https://www.ncbi.nlm.nih.gov/pubmed/37270698
http://dx.doi.org/10.1001/jamaoncol.2023.1962

Ejemplares similares